Endothelial LRRC8C associates with LRRC8A and LRRC8B to regulate vascular reactivity and blood pressure

Abstract Vascular tone is impacted by the endothelium’s ability to detect mechanical and chemical stimulation. Leucine-Rich Repeat-Containing protein 8A, (LRRC8A), was previously identified as a required component of the mechanoresponsive endothelial LRRC8 complex regulating AKT-endothelial nitric oxide synthase (eNOS) signaling and vascular function. While LRRC8A is broadly expressed, LRRC8B, C, D and E have tissue-restricted expression. Here, we identified 2 single nucleotide polymorphisms (SNPs) in LRRC8C highly associated with elevated diastolic and systolic blood pressure in human genetic studies, implicating LRRC8C as a regulator of vascular function. While LRRC8A/B/C/D/E are expressed in endothelium, co-immunoprecipitation experiments from lung endothelium using Lrrc8a-3xFlag knock-in mice, Lrrc8c-HA knock-in mice and endothelium-specific Lrrc8a-3xFlag overexpression mice demonstrate the endothelial LRRC8 complex to be composed largely of LRRC8A/B/C heteromers. Lrrc8a/b/c knock-out studies in mice and knock-down studies in human umbilical vein endothelial cells show co-dependent expression of LRRC8A/B/C proteins, but not LRRC8D. Functionally, LRRC8A and LRRC8C depletion reduces endothelial volume regulatory anion channel (VRAC) currents, inhibits AKT-eNOS signaling, increases myogenic tone, impairs eNOS dependent vasodilation, and exacerbates angiotensin-induced hypertension. These data identify LRRC8A, LRRC8B and LRRC8C as components of the endothelial LRRC8 complex and reveal LRRC8C as having a non-redundant role in regulating endothelial AKT-eNOS, vascular relaxation and susceptibility to hypertension. Competing Interest Statement R.S. is co-founder of Senseion Therapeutics, Inc., a start-up company developing SWELL1 modulators for human disease. D.J.L. is co-founder and CEO of Senseion Therapeutics, Inc. The remaining authors declare that no conflict of interest exists.